Live tape
Top 8, mentions 7d18,258MSFT3,395 mentions▲ +0.09AAPL2,656 mentions▲ +0.07GOOGL2,634 mentions▲ +0.05META2,225 mentions▲ +0.04SNDK2,157 mentions▲ +0.06NVDA1,838 mentions▲ +0.07SPCX1,708 mentions▲ +0.06AMZN1,645 mentions▲ +0.10

Equity · Healthcare

NBIX

Neurocrine Biosciences, Inc. · NasdaqGS

$170.78 −0.13% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of NBIX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 54 sessions over that window: $134.02 on 4 May 2026 through $170.78 on 17 July 2026. Finazon · prior-day close.

Market cap $17.4B
P/E (TTM) 26.7
52-week range $121.00 – $181.00
Avg volume 228.7K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 2, 2026

NBIX insider trades

SEC Form 4 · last 90 days · newest reported trade 28 Jul 2026
Open-market buys 0
Open-market sells 18
Net sold $62.45M
Non-trade filings 27
Date Insider Type Shares Value
28 Jul 2026 Norwalk Leslie V Director Sell 1,250 $228K
10 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 4,367 $791K
09 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 8,433 $1.51M
09 Jul 2026 Lippoldt Darin Chief Legal Officer Sell 10,000 $1.80M
08 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 2,737 $489K
07 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 3,401 $607K
29 Jun 2026 Lippoldt Darin Chief Legal Officer Sell 9,800 $1.67M
26 Jun 2026 Lippoldt Darin Chief Legal Officer Sell 200 $34K
05 Jun 2026 SHERWIN STEPHEN A Director Sell 25,000 $4.13M
04 Jun 2026 Norwalk Leslie V Director Sell 1,250 $210K
02 Jun 2026 Cooke Julie Chief Human Resources Officer Sell 36,937 $5.77M
01 Jun 2026 Onyia Jude Chief Scientific Officer Sell 11,000 $1.76M

Showing the 12 most recent of 18 open-market trades in this window. The figures above count all of them.

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
29 Jul 2026 Norwalk Leslie V Director Option exercise 842 $117K
10 Jul 2026 Delaet Ingrid Chief Regulatory Officer Option exercise 4,367 $463K
09 Jul 2026 Delaet Ingrid Chief Regulatory Officer Option exercise 8,433 $873K
09 Jul 2026 Lippoldt Darin Chief Legal Officer Option exercise 10,000 $815K
08 Jul 2026 Delaet Ingrid Chief Regulatory Officer Option exercise 2,737 $283K
07 Jul 2026 Delaet Ingrid Chief Regulatory Officer Option exercise 3,401 $352K
29 Jun 2026 Lippoldt Darin Chief Legal Officer Option exercise 9,800 $799K
26 Jun 2026 Lippoldt Darin Chief Legal Officer Option exercise 200 $16K
05 Jun 2026 SHERWIN STEPHEN A Director Option exercise 25,000 $1.60M
05 Jun 2026 Onyia Jude Chief Scientific Officer Gift 2,441
02 Jun 2026 Cooke Julie Chief Human Resources Officer Option exercise 24,965 $2.03M
02 Jun 2026 Keswani Sanjay Chandru Chief Medical Officer Option exercise 3,212

Showing the 12 most recent of 27 compensation filings in this window. The figures above count all of them.

NBIX reported financials

SEC EDGAR XBRL

NBIX reported revenue of $2.9B for the fiscal year ended 31 Dec 2025. Net income over the same period was $478.6M.

Figure Reported Period
Revenue $2.9B 31 Dec 2025 fiscal year
Net income $478.6M 31 Dec 2025 fiscal year
Diluted EPS $4.67 31 Dec 2025 fiscal year
Total assets $5.4B 30 Jun 2026 at period end
Total equity $3.7B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

NBIX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $1.39 —
31 Mar 2026 Q1 2026 $1.91 —
31 Dec 2025 FY 2025 $4.67 —
30 Sep 2025 Q3 2025 $2.04 —
30 Jun 2025 Q2 2025 $1.06 —
31 Mar 2025 Q1 2025 $0.08 —
31 Dec 2024 FY 2024 $3.29 —
30 Sep 2024 Q3 2024 $1.24 —

Reported figures & scheduled dates · SEC EDGAR filings

NBIX institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a NBIX position for the quarter ended 31 Mar 2026 — a combined $1.7B; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
AQR Capital Management Added +51.0% shares 4,938,967 $650.7M
Two Sigma Investments Added +210.8% shares 3,060,570 $403.2M
Renaissance Technologies Held (±25%) +8.0% shares 2,418,897 $318.7M
Millennium Management Added +181.7% shares 1,247,447 $164.3M
Marshall Wace Added +45.9% shares 508,977 $67.1M
Man Group Added +79.9% shares 415,909 $54.8M
Bridgewater Associates Held (±25%) −1.2% shares 148,141 $19.5M
Fisher Asset Management Held (±25%) +8.9% shares 122,226 $16.1M
D. E. Shaw & Co. New position 89,184 $11.7M
Citadel Advisors Trimmed −27.3% shares 57,968 $7.6M

Source: SEC EDGAR 13F filings

NBIX fails-to-deliver

SEC CNS data

On 09 Jul 2026, 382 shares of NBIX failed to deliver (about $68K).

Settlement date Shares failed Notional % of shares out
09 Jul 2026 382 $68K <0.001%
02 Jul 2026 360 $60K <0.001%
25 Jun 2026 201,605 $33.5M 0.201%

Source: SEC fails-to-deliver (CNS) data